Although Bayer Healthcare, headquartered in Leverkusen, Germany, spent most of 2006 in the spotlight because of its €16.3 billion ($19.6 billion) acquisition of Berlin-based Schering, its ongoing restructuring is bound to yield a total of three new German spin-offs to the ranks of Europe's independent life sciences companies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Rights and permissions
About this article
Cite this article
Sheridan, C. European pharma consolidation generates quality spinoffs. Nat Biotechnol 24, 1458–1459 (2006). https://doi.org/10.1038/nbt1206-1458
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1206-1458
